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Background: The variation of human papillomavirus (HPV) genes or HPV variants demonstrates different risks of
cervical cancer. Mutation in the long control region (LCR) at YY1-motifs is one of the mechanisms for enhancing
viral oncogene expression during the course of cancer cell progression. In Thai women, cervical cancers are almost
always associated with HPV16 variant sub-lineage Asian (HPV16As); however, the mechanism involved remains
elusive. The aim of this study was to understand further the oncogenic potential of HPV16As.
Methods: A total of 82 HPV16-positive specimens from Thai women were selected from formalin-fixed paraffin-
embedded cervical tissues, and the full length E6 gene of each specimen was amplified and sequenced. LCRs of
the HPV16As-positive cases were amplified and sequenced to analyze their polymorphisms. Transcriptional activities
of the HPV16As LCRs were then compared with sub-lineage European (EUR), sub-lineage Asian-American 1 (AA1)
and HPV16 prototype by insertion of the LCRs into the pGL3-Basic vector.
Results: The HPV16 DNA sequences were classified as HPV16 prototype (18.3%), Asian (As, 61%), Asian American-1
(AA1, 8.5%), European (EUR, 7.3%), Asian African-2 (AFR2, 3.7%) and Java-135C (J135C, 1.2%). The prevalence of
HPV16As was 30% in low-grade squamous intraepithelial lesion (LSIL), while that in high-grade squamous
intraepithelial lesion (HSIL) and squamous cell cervical carcinoma (SCC) were 63.9% and 66.7%, respectively, which
demonstrates a significant association of HPV16As with the disease severity. LCR polymorphisms from 43 HPV16As
positive cases were analyzed by PCR-sequencing. Thirty-eight nucleotide variation positions spanned nucleotide
positions 7157–82. Ten new mutations found in the HPV16As LCRs were located predominantly at the enhancer
and proximal to the 3’-end of the early promoter. The LCRs of the common HPV16As, EUR and AA1 showed 5, 13
and 23-fold higher activity than the HPV16 prototype LCR, while those of the new nucleotide variations of As
showed 19 (As-sv1) and 30 (As-sv14) -fold higher activity than the HPV16 prototype.
Conclusions: HPV16As DNA sequence variation, especially at the proximal to early promoter in the LCR, enhances
transcriptional activity. This could be one of the possible mechanisms for HPV16As-associated cervical cancer
development.
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Cervical cancer is the second most common cancer
among women worldwide, and it remains a leading
cause of cancer-related death in women in developing
countries [1]. The most important risk factor that is
associated with cervical cancer is infection with high-* Correspondence: tipeka@kku.ac.th
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reproduction in any medium, provided the orrisk human papillomaviruses (HR-HPVs), particularly
HPV16, which is the most prevalent type and is found in
approximately 55% of individuals with cervical cancer
[1,2]. Previous studies have shown that nucleotide
alterations in HPV16 affect the oncogenic potential of
the virus [3]. The first worldwide study of HPV16
variants was performed by Ho et al. in 1993 [4]. The
study reported that HPV16 long control region (LCR)
variants robustly segregate into a phylogenetic tree with
five major variant lineages that are named based on theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 HPV16 variant sub-lineages in each cervical
lesion
Sub-lineages LSIL (%) HSIL (%) SCC (%) Total (%)
Prototype 5 (50) 6 (16.7) 4 (11.1) 15 (18.3)
As 3 (30) 23 (63.9) 24 (66.7) 50 (61)
AA1 - 2 (5.5) 5 (13.9) 7 (8.5)
EUR 2 (20) 4 (11.1) - 6 (7.3)
AFR2 - 1 (2.8) 2 (5.5) 3 (3.7)
J135C - - 1 (2.8) 1 (1.2)
Total 10 36 36 82 (100)
LSIL = low-grade squamous intraepithelial lesion.
HSIL = high-grade squamous intraepithelial lesion.
SCC = squamous cell cervical carcinoma.
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used sequence analysis of several genes, including the E6
open reading frame (ORF), to demonstrate that HPV16
variants can be classified into six major variant lineages:
European (EUR), Asian (As), Asian American (AA),
African-1 (AFR-1), African-2 (AFR-2) and North Ameri-
can (NA). This analysis suggested that 26% of Southeast
Asian tissue samples contain the As variant lineage,
which is rare or absent in other continents. Cornet et al.
[5] confirmed variant lineages and sub-classifications
that provide nine HPV16 variant sub-lineages (EUR, As,
AFR1a, AFR1b, AFR2a, AFR2b, NA, AA1 and AA2)
based upon 13 and 32 phylogenetically distinct positions
in E6 and LCR, respectively.
Infection with HR-HPV induces carcinogenesis through
dysregulation of E6 and E7 oncogene expression, which is
controlled by the p97 early promoter that is located in
the E6 proximal part of the LCR. The HPV16 LCR is
approximately 850 bp and contains the early promoter
and various transcriptional regulatory motifs for both
viral and host proteins [6].
Transcriptional analysis of the HPV16 LCR is important
to evaluate the association between LCR sequence variation
and the oncogenic potential of HPV16 variants. Sequence
variations in the LCR of HPV16 may modulate the
oncogenic potential of HPV16, as nucleotide changes
within this regulatory region influence replication and
transcription through their effect on regulatory protein
complex formation on DNA [7]. A special role has been
assigned to variations that occur within YY1 binding sites
in the LCR, as these variations were found to enhance
expression of the viral oncoproteins [8]. Several groups
have reported different activities of HPV16 variants and,
as a result, have classified the variants into geographically
clustered phylogenetic groups [9-11].
Infection with HPV16 variant sub-lineage Asian
(HPV16As) is found predominantly in cervical cancer cases
with HPV16 positive (73.9%) in Khon Kean, Thailand [12],
yet data regarding the transcriptional activity of HPV16As
are absent. In the present study, we investigated the
association between the risk of cervical cancer and the
genetic variations of HPV16. For this purpose, we
analyzed the genetic polymorphisms in the LCR of
HPV16As. In addition, transcriptional activity of LCRs
from 4 DNA samples of HPV16As was examined and
compared to AA1, EUR and HPV16 prototype to establish
the role of infection in cervical carcinogenesis.
Results
The association of cervical cancer risk and HPV16As
All 82 HPV16-positive samples from Thai women were
investigated for HPV16 variant lineages or sub-lineages
according to Yamada’s classification using specific primer
sets for the HPV16 E6 gene. The most common HPV16variant sub-lineage was As (61%). The proportion of
HPV16As increased proportionally (OR 4.387; 95% CI
1.043-18.457; P = 0.042) with the severity of cervical
lesions (30% of LSIL, 63.9% of HSIL and 66.7% of SCC)
(Table 1).
Polymorphisms of LCRs among HPV16As
To investigate the mutations in the LCRs among
HPV16As, the 47 DNA samples from HPV16As- positive
cases with HSIL and SCC were studied. The HPV16As
LCRs from 43 cases were successfully amplified and
sequenced. Blast analysis was performed against HPV16
prototype LCR sequences [GenBank:AY686584] to evaluate
gene mutations.
A total of 38 nucleotide variation positions was found in
a region spanning nucleotide positions 7157–82 in the
HPV16As LCR (Table 2). At least 22 of these nucleotide
alterations were previously reported by other authors
[10,13]. In addition, we found 10 nucleotide variation
positions that have not been previously reported, including
7218 T>A, 7384 T>G, 7429 G>A, 7430C>T, 7617C
insertion with A, 7844A>C, 7874C>G, 28 G insertion with
A (SP-1), 46 T insertion with G (SP-1, E2BS-2) and 61 T
insertion with G (E2BS-1). This result shows that the
HPV16As polymorphisms have a specific combination of
12 specific nucleotide variations in the LCR, of which six
are diagnostic: 7177 T>C, 7201 T>C, 7270C>T, 7287A>C,
7842 G>A/T and 24C>T. According these mutations,
37.2% (18.6% of each SCC and HSIL) were recognized as
common HPV16As. HPV16As sub-variant (As-sv) was
identified as As-sv1-22 depending on different nucleotide
mutations (Table 2).
Nucleotide sequence alterations were also detected
within the binding site of TEF-1 (7193 G>T), YY-1, SP-1
and OCT-1 (7842 G>A or T) in the LCRs of all 43
HPV16As cases (100%). Additionally, five nucleotide
changes in HPV16As LCRs were found within known
binding sites of GRE-1 (7485A>C and 7489 G>A), YY-1
(7781 T>C and 7802C>A) and E2BS-3 (7868 G>A), with
Table 2 Nucleotide variations in HPV16As LCRs from HSIL and SCC samples compared with the HPV16 LCR reference sequence [GenBank:AY686584]
HPV16 LCR
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Binding site TEF-1 GRE-1 GRE-1
% of samples 100 100 7 2.3 100 100 2.3 2.3 4.7 95.3 100 95.3 4.7 2.3 2.3 41.9 4.7 2.3 2.3 100
Changed position 7175 7177 7179 7186 7193 7201 7213 7217 *7218 7270 7287 7289 *7384 7405 7418 *7429 *7430 7485 7489 7521
HPV16 pt. A T G T G T G G T C A A T T T G C A G G
HPV16 As C C - - T C - - - - C - - - - - - - - A
SCC
As C C - - T C - - - T C C - - - - - - - A
As-sv1 C C - - T C - - - T C C - - - A - - - A
As-sv2 C C - G T C - - - T C C - - - - - - - A
As-sv3 C C - - T C - A - T C C - - - - - - - A
As-sv4 C C - - T C - - A T C - - - - - - - - A
As-sv5 C C - - T C - - - T C T G - - - T - - A
As-sv6 C C - - T C - - - T C T G - - - T - - A
As-sv7 C C - - T C - - - T C - - G - - - - - A
As-sv8 C C - - T C - - - T C C - - A A - - - A
As-sv9 C C - - T C - - - T C C - - - - - - - A
As-sv10 C C - - T C - - - T C C - - - - - - - A
As-sv11 C C - - T C - - - T C C - - - - - - - A
As-sv12 C C - - T C - - - - C C - - - - - C A A
As-sv13 C C - - T C - - - T C C - - - A - - - A
As-sv14 C C - - T C - - - T C C - - - - - - - A
As-sv15 C C - - T C - - - T C C - - - - - - - A
As-sv16 C C - - T C - - - T C C - - - A - - - A
HSIL
As-sv1 C C - - T C - - - T C C - - - A - - - A
As-sv17 C C T - T C - - - T C C - - - A - - - A
As-sv18 C C - - T C - - - T C C - - - A - - - A
As-sv19 C C T - T C C^ - - T C C - - - - - - - A
As-sv20 C C - - T C - - A - C C - - - A - - - A
As-sv21 C C - - T C - - - T C C - - - A - - - A

















21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38
Binding site YY-1 YY-1 YY-1, SP-1, OCT-1 E2BS-3 SP-1 SP-1, E2BS-2 E2BS-1
% of samples 2.3 2.3 100 9.3 2.3 2.3 2.3 2.3 100 2.3 2.3 39.5 2.3 100 4.7 4.7 4.7 100
Changed position *7617 7623 7730 7781 7791 7792 7802 7813 7842 *7844 7868 *7874 7886 24 *28 *46 *61 81
HPV16 pt. C G A T T C C T G A G C C C G T T G
HPV16 As - - C - - - - - A/T - - - - T - - - -
SCC
As - - C - - - - - A - - - - T - - - T 8 (18.6%)
As-sv1 - - C - - - - - A - - G - T - - - T 4 (9.3%)
As-sv2 - - C C - T - - T - - - - T - - - T 1 (2.3%)
As-sv3 - C^ C - - - - - A - - - - T - - - T 1 (2.3%)
As-sv4 - - C - - - - - A - - - - T - - - T 1 (2.3%)
As-sv5 - - C - - - - - A - - - - T - - - T 1 (2.3%)
As-sv6 - - C - - - A - A - - - - T - - - T 1 (2.3%)
As-sv7 - - C - - - - - A - - - - T - - - T 1 (2.3%)
As-sv8 A^ - C - - - - - A - - G - T - - - T 1 (2.3%)
As-sv9 - - C C - - - - A - - - - T - - - T 1 (2.3%)
As-sv10 - - C C - - - - T C - - - T - - - T 1 (2.3%)
As-sv11 - - C C - - - - A - - G - T - - - T 1 (2.3%)
As-sv12 - - C - - - - - A - - - - T - - - T 1 (2.3%)
As-sv13 - - C - - - - - A - - G - T - G^ - T 1 (2.3%)
As-sv14 - - C - - - - - A - - G - T A^ G^ G^ T 1 (2.3%)
As-sv15 - - C - - - - - A - - - - T A^ - G^ T 1 (2.3%)
As-sv16 - - C - del - - G^ A - - - - T - - - T 1 (2.3%)
HSIL
As-sv1 - - C - - - - - A - - G - T - - - T 8 (18.6%)
As-sv17 - - C - - - - - A - - - - T - - - T 2 (4.7%)
As-sv18 - - C - - - - - A - - - - T - - - T 2 (4.7%)
As-sv19 - - C - - - - - A - - G - T - - - T 1 (2.3%)
As-sv20 - - C - - - - - A - - - - T - - - T 1 (2.3%)
As-sv21 - - C - - - - - A - A G - T - - - T 1 (2.3%)
As-sv22 - - C - - - - - A - - G A T - - - T 1 (2.3%)
*Novel nucleotide sequence variation found in this study, HPV16pt. = HPV16 prototype [GenBank:AY686584], As = HPV16As, As-sv = HPV16As sub-variant, TEF-1 = transcription factor binding site, GRE-1 = glucocorticoid














Figure 1 Transcriptional activity of the LCRs from the HPV16
prototype, As, As-sv1, As-sv14, AA1 and EUR. The transcriptional
activity was determined by luciferase activity in the C33A cell line,
and the relative luciferase activity of HPV16As was compared to the
prototype. The data presented represent average of at least 3
independent experiments, with error bars indicating
standard variations.
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respectively. The novel nucleotide alterations found in
this study at positions 7429 G>A and 7874C>G were the
most common variations, with a prevalence of 41.9% and
39.5%, respectively. Moreover, 4.7% of the 43 samples
exhibited a nucleotide change proximal to the p97 pro-
moter, especially at positions 46 and 61, which correspond
to the binding sites for SP-1, E2BS-2 and E2BS-1.
HPV16As LCR transcriptional activity
To determine the consequences of HPV16As LCR
nucleotide sequence variation, the transcriptional activity
of HPV16As LCRs was compared with that of HPV16
prototype and the sub-lineages, AA1 and EUR. Nucleotide
variations in the LCRs from HPV16As, As-sv1, As-sv14,
AA1 and EUR are proximal to the p97 promoter for the
E6/E7 oncogenes and are shown in Table 3. The common
HPV16As (no. 15 and 36) contains LCR isolated from
HSIL and SCC. The HPV16As-sv1 and HPV16As-sv14
contain HPV16As LCR mutations at positions which are
reported for the first time in this study as novel variation:
7429 G>A, 7874C>G, 28 G insertion with A (SP-1), 46 T
insertion with G (SP-1, E2BS2) and 61 T insertion with G
(E2BS1).
Figure 1 shows LCR transcriptional activities, and the
results indicate that all of the HPV16As, EUR and AA1
LCRs show higher transcriptional activity than the
prototype. Both HPV16As-sv1 and HPV16As-sv14
exhibited higher transcriptional activity than the com-
mon HPV16As and the HPV16As-sv14 showed the
highest transcriptional activity with 30-fold higher activ-
ity than the prototype.
Discussion
HPV16 intratypic variants have been extensively studied.
It has been proposed that HPV16 variants with E6 se-
quence variation are most closely related to the risk fac-
tor for development of squamous intraepithelial lesionsTable 3 The positions of nucleotide variation in LCRs from th
nt. position 7177 7193 7201 7270 7287 7289 7429
Prototypea T G T C A A G
Asb (no. 15) C T C T C C G
Asb (no. 36) C T C T C C G
As-sv1c (no. 30) C T C T C C A
As-sv14c (no. 42) C T C T C C A
nt. position 7193 7233 7339 7394 7395 7485 7489
Prototypea G A A C C A G
EUR (no. 43) G A A C C A G
AA1 (no. 47) T T T T T C A
aHPV16 prototype LCR, the reference sequence [GenBank:AY686584].
bHPV16As LCR, the sequence found in previous studies in other continents.
cHPV16As sub-variant LCR, the novel sequence variation reported in this study.and invasive carcinoma [14]. In the present study,
HPV16 prototype (18.3%) and the 5 different HPV16
variant sub-lineages, As (61%), AA1 (8.5%), EUR (7.3%),
AFR2 (3.7%) and J135C (1.2%), were detected (Table 1).
The HPV16As detection rate increased according to the
severity of the lesion, 30% of LSIL, 63.9% of HSIL and
66.7% of SCC. This result shows that HPV16As infection
is associated with a high risk of HSIL and SCC develop-
ment with an odds ratio of 4.387; 95% CI 1.043-18.457;
P = 0.042 compared to prototype and other sub-lineages.
Moreover, in comparison to HPV16 prototype, this re-
sult shows an increased association of HPV16As with
risk for cervical cancer. This study suggests that
HPV16As is an oncogenic risk for cervical cancer
progression.
A study of HPV16 variants in Khon Kaen, Thailand
found HPV16As in 73.9% of HPV16-positive cervical
cancer samples and showed a risk association with CIN
II-III and SCC [12]. Our previous and present studies
confirmed the strong association of HPV16As withe HPV16 variant sub-lineages
7521 7730 7842 7874 24 28 46 61 81
G A G C C G T T G
A C A C T G T T T
A C A C T G T T T
A C A G T G T T T
A C A G T A^ G^ G^ T
7521 7669 7689 7729 7743 7764 7786 7886 28
G C C A T C C C G
A C C A T C C C A^
A T A C G T T G G
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studies have shown that infection with HPV16 prototype
is associated with a lower risk in progression to cervical
cancer than that caused by other variants. Sequence
variation among HPV16 variants may influence the
event of HPV persistence and progression to CIN and
cervical carcinoma [9,15].
Using the HPV16 prototype [GenBank:AY686584] as a
reference sequence, we detected a total of 38 nucleotide
variation positions in the LCRs of 43 HPV16As cases.
This result agrees with previous reports of a HPV16As-
specific nucleotide variation in the LCR at position 7842
[16-18]. At this position (7842), the majority of the LCR
samples had a nucleotide change from G>A (90.7%),
whereas the remaining samples had a G>T change. We
also identified additional nucleotide variations at
positions 7175A>C, 7177 T>C, 7193 G>T, 7201 T>C,
7287A>C, 7521 G>A, 7730A>C, 24C>T and 81 G>T,
which were found in all (100%) samples. Other common
variations were 7270C>T (95.3%) and 7289 A>T (95.3%).
These sequence variations may be typical of the LCR
from HPV16As in this region (Table 2).
In this study, 10 novel nucleotide variations, which
were previously unreported in the literature, were found
in HPV16As LCRs (Table 2); however, two of them were
found in only one sample (7617C>A and 7844A>C) and
may have occurred by PCR amplification. These
variations were associated with YY-1 binding sites, and
among them, a deletion or substitution was found to
enhance early promoter transcription. It was suggested
that mutation affecting YY1-motifs in the LCR is one of the
mechanisms that enhance viral oncogene expression during
the course of cancer cell progression [19]. Additionally,
several studies have reported that cellular factors, such as
AP-1, GRE, NF-1, NF-IL6, OCT-1, SP-1, TEF-1, TEF-2
and YY-1, either stimulate or inhibit p97 promoter activity
[20-22]. Therefore, these variations could be related to the
early promoter activation of HPV16As. With respect to
positions 7429 G>A, 7874C>G, 28 G insertion with A,
46 T insertion with G and 61 T insertion with G, these
mutations are located close to E2BS-4 (nt 7453–7464),
E2BS-3 (nt 7860–7871), SP-1 and E2BS-2 (nt 35–46)
and E2BS-1 (nt 50–61), respectively [11]. These novel
nucleotide variations in the LCR of HPV16As may play
a crucial role in the transcriptional modulation of the
HPV16 E6 and E7 oncogenes via the p97 promoter.
Lace et al. [7] reported that p97 promoter activity of
CAT reporter containing different LCR mutation in
HeLa cell line. The results showed that transcriptional
activity of HPV16As LCR variations was higher than
that of the HPV16 prototype.
The HPV16As isolated from samples no. 15 (HSIL case)
and 36 (SCC case) with common nucleotide variation in
the LCR (Tables 2 and 3) showed an approximate 5-foldincrease in p97 promoter activity compared to the proto-
type. In accordance with previous results [13], EUR and
AA1 transcriptional activity studied in the present study
also show higher activity than prototype. This study also
shows higher activity of EUR than common HPV16As.
Interestingly, the activity of AA1 has similar patterns
to the LCR from the HPV16As-sv1 and HPV16As-sv14
which contained novel variations proximal to the p97
promoter that showed transcriptional activity with 19
and 30-fold higher activity than the prototype. These
data suggest that novel nucleotide changes at 7429 G>A
and 7874C>G, which are proximal to p97 (at positions 28,
46 and 61) in the LCRs from HPV16As, are associated with
high transcriptional activity. Therefore, the oncogenic
potential of HPV16As could be influenced by specific
sequence variation, especially at positions that are proximal
to the promoter region in the HPV16 LCR.
Veress et al. [10] reported transcriptional activity of
LCRs from AA HPV16 variants by luciferase assay in
C33A cells. The results showed a 1.7-fold increase in
transcriptional activity with the AA isolate LCR and a very
similar transcriptional activity with the EUR LCR
compared to that with the LCR reference. This increased
activity of the AA isolate could be attributed to nucleotide
changes found at the 3’ end of the LCR (nt7660-7890).
In addition, in 2001 Veress et al. [13] showed that the
transcriptional activity of HPV16 full-length AA and EUR
isolated from clinical specimens was higher than prototype.
Kammer et al. [11] reported that 3.3- and 2.8-fold
increases in p97 promoter activity were detected in the
Asian American c (AAc) and North American 1 (NA-1)
variants, respectively, when compared with the European
reference clone. The region in the AAc and NA-1
variants that is responsible for enhanced transcription
could be the E6-proximal end of the LCR (nt 7619–124).
Similar results were obtained by Veress et al. [13], who
showed that the enhanced transcriptional activity of the
AAc variant was due to nucleotide changes in the 3’
region of the LCR. However, a deletion variant lacking
the whole enhancer and both silencer regions, either the
YY-1-specific silencer alone or together with the CDP-
specific silencer, retained substantial enhancer activity
on the p97 promoter. Chen et al. [23] studied mutations
in the LCR and their functional consequences in oral
cancer. They found that promoter activity of the
mutated HPV16 LCR was significantly higher than that
of the wild type HPV16 LCR, suggesting that mutations
in the LCR of HPV in oral cancer leads to increased
expression of the E6/E7 oncoproteins, which might
contribute to the carcinogenic process.
Conclusion
Several nucleotide sequence variations were found in the
LCR of HPV16As and showed specific patterns in Thai
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to the alternative mechanism involved in HPV16 onco-
genicity and demonstrate a correlation between HPV16 in-
fection and progression to cervical cancer in Thai women.
Therefore, our study provides important information
concerning the biological significance of intratype genomic




A total of 82 samples of HPV16 positive DNAs were
selected from our previous study [24] that was performed
with 410 archival formalin-fixed paraffin-embedded (FFPE)
cervical tissues of Thai women. The samples were used for
a study that purposed to investigate the function of HPV16
variants, E2 and LCR polymorphism, and is approved by
the Khon Kaen University Ethics Committee for Human
Research, as per the Helsinki Declaration with reference
number HE500813. The DNA samples were extracted from
cervical tissues that were histologically diagnosed as low-
grade squamous intraepithelial lesions (LSIL, 10 cases),
high-grade squamous intraepithelial lesions (HSIL, 36 cases)
and squamous cell carcinoma (SCC, 36 cases).
HPV16 variant determination
DNA from the selected cases was used as a template to
amplify the full-length HPV16 E6 gene by PCR using 3
primer pairs (Table 4) according to the methods of de
Boer et al. [25]. Amplicons were analyzed by 1.5%
agarose gel electrophoresis, purified and sequenced
using an automated sequencer provided by the Molecular
Informatics Laboratory, Hong Kong.Table 4 Primers used for HPV16 E6 gene and HPV16 LCR
amplification
Primers Sequences (5’ to 3’) Positions Product
size (bp)
E6-1 F TTGAACCGAAACCGGTTAGT nt 46–65 211
E6-1R GCATAAATCCCGAAAAGCAA nt 237–256
E6-2 F GCAACAGTTACTGCGACGTG nt 204–224 235
E6-2R GGACACAGTGGCTTTTGACA nt 419–438
E6-3 F CAGCAATACAACAAACCGTTG nt 371–391 220
E6-3R TCATGCAATGTAGGTGTATCTCC nt 568–590
LCR1-F GAAAACGAAAAGCTACACCCA nt 7083-7104 286
LCR1-R CAATGAATAACCACAACACAATTA nt 7345-7368
LCR2-F GCTTGTGTAACTATTGTGTCATG nt 7289-7311 292
LCR2-R GTGCAGGTCAGGAAAACAG nt 7562-7580
LCR3-F ACTTGTACGTTTCCTGCTTG nt 7525-7544 350
LCR3-R GTGTAACCCAAAATCGGTTTGC nt 7853-7874
LCR4-F GTCACCCTAGTTCATACATGA nt 7777-7797 231
LCR4-R TGCAGTTCTCTTTTGGTGC nt 85-103Analysis of HPV16As LCR polymorphisms
Forty-seven DNA samples from the HSIL and SCC cases
were classified as HPV16As and investigated for LCR
polymorphisms.
Four primer pairs were designed for LCR sequence
amplification (Table 4). A 50 μl PCR mixture consisted
of 10x PCR buffer, 2.5 mM MgCl2, 10 mM dNTP, 1 U
Taq DNA polymerase, 10 pM specific primers and 3 μl
of DNA template. PCR products were analyzed by 1.5%
agarose gel electrophoresis and sequenced by the
Molecular Informatic Laboratory, Hong Kong. Nucleotide
sequences of amplified LCRs were aligned and compared
with the HPV16 reference sequence [GenBank:AY686584],
using the bioinformatics genomic tool, Multalin. The
HPV16 prototype used in this study was obtained from an
HPV16 reference plasmid (kindly provided by Prof. Dr.
Ethel-Michele de Villiers), and the sequence was confirmed
to correspond with AY686584, which is available through
the GenBank database.
Plasmid construction
Four samples of HPV16As and the sub-lineages, AA1
and EUR, from SCC cases that were found in this study
were selected for plasmid construction. Two samples
(no. 15 and no. 36) have nucleotide variations in the LCR
that are commonly found in HPV16As. The other two
(no. 30 and no. 42) have different nucleotide variations in
the LCR sequence (Table 2 and 3). The LCR of the
HPV16 reference plasmid was also used for plasmid
construction to compare the transcriptional activity.
Full-length LCRs containing the HPV16 promoter,
p97, for oncogenes E6 and E7 were amplified by PCR
using forward LCR1 and reverse LCR4 primers (Table 4).
The amplified full-length LCR PCR product was ligated
into the pDRIVE cloning vector (Qiagen, Hilden, Germany)
and subcloned into the promoterless luciferase reporter
vector, pGL3-Basic (Promega, Madison, WI, USA). The
constructed vectors were verified by sequencing.
Transcriptional activity analysis
The pGL3 vectors containing LCRs from HPV16 prototype,
four samples of HPV16As, one sample of AA1 and one
sample of EUR were used for transcriptional analysis.
C33A, a human cervical cancer cell line, was transiently
transfected with 0.8 μg of the plasmid vectors using
Lipofectamine 2000 (Invitrogen Life Technologies,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. The cells were harvested at various times
(12, 24 and 48 hours) after transfection to optimize the
activity. The transfected cells were analyzed by the
Bright-Glo™ luciferase assay reagent (Promega, Madison,
WI, USA). Luciferase activity was determined using a
Modulus Single Tube Multimode Reader (Turner
Biosystem). The pSV-β galactosidase control vector
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SV40 early promoter and enhancer upstream of the
Lac Z gene, was used to control for transfection
efficiency and luciferase activity.
Statistic analysis
The Chi-square test was used to analyze the correlation
between the HPV16 variant sub-lineages and cervical
cancer. Student’s t-test was used to analyze the transcrip-
tional activity of the HPV16 prototype and HPV16As. A
P value of less than 0.05 was considered as statistically
significant. The risk of HPV16As that associated with
different grade lesions was analyzed using odds ratio
(OR) and 95% confidence interval (CI). The analysis was
performed with a SPSS16 program.
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